Palmoplantar pustulosis
MONDO:0015597A rare skin disease characterized by chronic eruption of sterile pustules on an erythematous and desquamative background, affecting the palms and soles, sometimes also the lateral aspects of hands and feet. The lesions are usually painful. Nail lesions (such as nail pitting, onycholysis, subungual pustules, and nail dystrophy) are also observed. The condition takes a chronic and relapsing course. Typical associations are psoriatic arthritis, thyroid gland dysfunction, and smoking.
Also known as: LPP, PPP, Palmoplantar Pustulosis, localised pustular psoriasis, localized pustular psoriasis, palmoplantar pustulosis, pustulosis of palm and sole, pustulosis palmaris et plantaris
45 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Promising drug for hand and foot blisters falls short in early trial
Disease control TerminatedThis study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug hope for painful hand and foot pustules
Disease control TerminatedThis trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Spesolimab shows promise for Long-Term control of painful hand and foot pustules
Disease control TerminatedThis study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Psoriasis drug trial for sensitive areas halted early
Symptom relief TerminatedThis study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC